AMWatch

Kapitalfond forlænger købstilbud på Karo Pharma efter vigende interesse og formands død

Det har vist sig sværere end ventet for kapitalfonden EQT at få aktionærerne til at tage mod opkøbstilbuddet i det svenske medicinalselskab Karo Pharma, hvis formand forleden pludselig døde. Det får nu kapitalfonden til at forlænge tidsfristen for opkøbet.

Aktionærerne i det svenske helse- og medicinalselskab Karo Pharma får forlænget fristen for at nikke til købstilbud fra EQT på 5,97 mia. svenske kr. | Photo: Colourbox

Tæt på og alligevel så langt fra.

Interessen blandt ejerne af det svenske helse- og medicinalselskab Karo Pharma for at lade sig opkøbe af kapitalfonden EQT er mindre end forventet.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Norway has the fastest growing investment fund market in Europe

So far in 2021, Norway has experienced massive inflows to its investment fund markets, beating former records. The pandemic and different government initiatives have resulted in an increased savings rate. Data also show that market shares are shifting among Norwegian fund managers.

Related articles

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch